ReviewEFORT open reviews2026
Intraosseous platelet-rich plasma for osteoarthritis: a comprehensive review.
Review in EFORT open reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intraosseous platelet-rich plasma (IO-PRP) therapy is an emerging biologic approach targeting the osteochondral unit in osteoarthritis (OA), especially of the knee and hip, by addressing subchondral bone pathology implicated in disease progression. This review synthesizes clinical and preclinical evidence on IO-PRP from PubMed and Scopus (up to May 2025), focusing on its biological rationale, therapeutic efficacy, and applications in osteoarticular disease. Evidence from randomized trials, observational studies, and experimental models indicates that IO-PRP - particularly when combined with intra-articular PRP - improves pain, function, and joint structure in moderate-to-severe OA. Preclinical studies demonstrate IO-PRP's role in subchondral bone remodelling, mesenchymal stromal cell modulation, and inflammation reduction, supporting its disease-modifying potential. IO-PRP represents a promising, biologically grounded intervention for OA management; however, further standardized, long-term clinical trials are needed to determine optimal protocols and validate long-term benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.